We do not have an idea if the COVID test distinguishes between viral diseases (eg RSV, influenza, COVID). These specific viruses are not specified in the ResApp Dx. This needs to be done IMO for the test to be at all worthwhile (and accepted from a regulatory point of view). Otherwise it is a test for a “viral respiratory disease” versus “non viral resp disease” or, even less usefully, normal. While interesting, and the result could be clinically useful, the whole point is to have an app for COVID surveillance, not for viral respiratory
Infections as a group I would think.
Further work is needed by the company. I
believe the potential COVID app is oversold as a product but I am certainly very happy to be proven wrong and hope all holders make a killing.
If I am wrong it is certainly worth a lot of money. Too risky for me though.
RAP Price at posting:
11.0¢ Sentiment: None Disclosure: Not Held
